CCNE1 and ovarian cancer: In ovarian cancer, the near mutual exclusivity of homologous recombination pathway mutations and CCNE1 amplification generally results in resistance to platinum-based cytotoxic chemotherapies and ineffective Poly (Adenosine Diphosphate (ADP)-Ribose Polymerase (PARP) inhibition [54].